Articles From: Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins in Patients With Diabetes Who Require High Doses of Insulin to BioLife Solutions Names Pharmaceutical Industry Expert Kevin O'Donnell as Vice President, Cold Chain Standards, Practices & Compliance


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G029661-001&sourceType=1 http://www.marketwire.com/library/MwGo/2015/1/6/11G029661/Biodel-Life-Delivered_000-1401197537254-220269572145.jpg DANBURY, CT--(Marketwired - January 07, 2015) - Biodel Inc. (NASDAQ: BIOD) announced positive preliminary results from Study 3-151, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to Humalog ® Mix 75/25 and Humulin ® R U-500 in patients with type 1 and type 2 diabetes with severe insulin resistance who use at least 150 units of insulin per day or at least 100 units of insulin in a single injection.
Sign-up for Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins in Patients With Diabetes Who Require High Doses of Insulin investment picks
Top line data anticipated by end of first quarter 2015 RALEIGH, N.C. , Dec.
Sign-up for BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy investment picks
BUNAVAIL Is the First and Only Buccal Film Formulation of Buprenorphine and Naloxone for the Maintenance Treatment of Opioid Dependence BUNAVAIL Shipped to Wholesalers; Pharmacy Availability Anticipated by End of This Week RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences Announces the Availability of BUNAVAIL™ in the U.S. investment picks
Website and Mobile App Offer Comprehensive Array of Information and Resources to Support Patients and Their Families RALEIGH, N.C. , Dec.
Sign-up for BioDelivery Sciences Launches InReach Support Program for Those Affected by Opioid Dependence investment picks
BUNAVAIL™ (buprenorphine and naloxone) buccal film now available by prescription for the maintenance treatment of opioid dependence Positive top-line results from second Phase 3 BEMA Buprenorphine clinical trial in chronic pain; recent pre-NDA meeting confirmed NDA submission on track for year-end or early 2015 Positive interim analysis completed in Phase 3 trial of Clonidine Topical Gel for painful diabetic neuropathy; Top-line results anticipated by end of first quarter 2015 Agreement signed to develop and commercialize long-acting, injectable, microparticle formulation of buprenorphine for opioid dependence and pain to compliment current portfolio RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2014 Financials investment picks
Complementary to BUNAVAIL™; Potential to Leverage Current Addiction Sales Force RALEIGH, N.C. , Oct.
Sign-up for BioDelivery Sciences to Develop a Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik for Use in Opioid Dependence and Pain investment picks
RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences to Present at the 26th Annual Piper Jaffray Healthcare Conference investment picks
RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences to Present at the Credit Suisse 2014 Healthcare Conference investment picks
By Russ Britt, MarketWatch Stock leaps as new treatment leap past a testing step LOS ANGELES (MarketWatch) -- Plans by Biogen Idec Inc. to move directly from Phase I to Phase III testing on an Alzheimer's treatment boosted shares of the company nearly 7% early Tuesday.
Sign-up for Biogen Alzheimer's drug skips to Phase 3 testing investment picks
Biogen Idec (NASDAQ: BIIB) and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches.
Sign-up for Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research investment picks
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of ELOCTA ™ (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A.
Sign-up for Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review investment picks
Biogen Idec (NASDAQ: BIIB) today announced top-line results from the Phase 2 acute optic neuritis (AON) RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system.
Sign-up for Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis investment picks
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the 2014 Deutsche Bank BioFEST Conference.
Sign-up for Biogen Idec to Present at the 2014 Deutsche Bank BioFEST Conference investment picks
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the 33 rd Annual J.P. Morgan Healthcare Conference.
Sign-up for Biogen Idec to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
Biogen Idec (NASDAQ: BIIB) will present data supporting its approved hemophilia therapies at the 56 th Annual Meeting of the American Society of Hematology (ASH) taking place in San Francisco, December 6-9.
Sign-up for Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting investment picks
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2014 financial results on Wednesday, January 28, 2015, before the financial markets open.
Sign-up for Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015 investment picks
Biogen Idec's (BIIB) stock was up 6.2% after the company reported Thursday that a treatment for acute optic neuritis it has developed proved to be effective in the second phase of a research study.
Sign-up for Biogen rises 6.2% after strong study results investment picks
Biogen Idec's stock (BIIB) jumped 10% in premarket trade Tuesday, after the biotechnology company said it was planning "very aggressively" to start a Phase 3 study program for its Alzheimer's treatment.
Sign-up for Biogen's stock surges on upbeat outlook for Alzheimer's treatment investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today reported that Alexander K.
Sign-up for Biolase Announces Management Change investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced a variety of advances and activities for the upcoming Greater New York Dental Meeting 2014 including the introduction of a new generation EPIC X diode laser, designed to be the premier and complete diode laser for the whole dental team.
Sign-up for BIOLASE Introduces a New Commitment to Customer Care, Quality and Innovation at Greater New York Dental Meeting 2014 investment picks
Newest innovation from market-leading dental laser manufacturer optimizes the dental experience for dentists, their staff members and their patients IRVINE, Calif.
Sign-up for BIOLASE Launches New EPIC™ X diode laser in the United States; Now Dentists Can Delight Their Patients, Faster investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading manufacturer and distributor of dental lasers, today reported unaudited financial results for the third quarter and nine months ended September 30, 2014.
Sign-up for BIOLASE Reports 2014 Third Quarter Results investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading dental laser manufacturer and distributor, announced today that investors including Jack W.
Sign-up for BIOLASE to Raise $35 Million from Institutional and Individual Investors in Private Placement investment picks
BIOLASE, Inc. (NASDAQ:BIOL), the world’s leading dental laser manufacturer and distributor, announced today that the Company will host a conference call on Tuesday, November 4th, at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter and nine months ended September 30, 2014, and to answer questions.
Sign-up for BIOLASE® to Host Third Quarter Financial Results Conference Call on November 4, 2014 investment picks
Conference Call and Webcast at 4:30pm Eastern Time BOTHELL, Wash.
Sign-up for BioLife Solutions Announces Third Quarter 2014 Results investment picks
Proprietary, Clinical Grade HypoThermosol® and CryoStor® Extending Shelf Life and Improving Survival & Function of CAR-T Cells, Dendritic Cells, Etc.
Sign-up for BioLife Solutions Biopreservation Media Products Embedded in 175 Cellular Immunotherapy & Other Regenerative Medicine Clinical Trials investment picks
Single-Use Syringes and Bulk Dispensing Bags with Sterile Dockable Tubing Offer Improved Aseptic Processing of Clinical Cells and Tissues BOTHELL, Wash.
Sign-up for BioLife Solutions Launches Two New Product Packaging Options for BloodStor® and CryoStor® Freeze Media investment picks
Key Executive Will Support Adoption of biologistex(SM) Cold Chain Management Service and EVO™ Smart Containers for Temperature Sensitive Biologics BOTHELL, Wash.
Sign-up for BioLife Solutions Names Pharmaceutical Industry Expert Kevin O'Donnell as Vice President, Cold Chain Standards, Practices & Compliance investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins in Patients With Diabetes Who Require High Doses of Insulin to BioLife Solutions Names Pharmaceutical Industry Expert Kevin O'Donnell as Vice President, Cold Chain Standards, Practices & Compliance
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent